Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−32.5152 USD
−25.26 M USD
0.00 USD
4.85 M
About Panbela Therapeutics, Inc.
Sector
Industry
CEO
Jennifer K. Simpson
Website
Headquarters
Waconia
Founded
2011
FIGI
BBG0186G10C4
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of PBLA is 0.2371 USD — it has decreased by −3.39% in the past 24 hours. Watch Panbela Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Panbela Therapeutics, Inc. stocks are traded under the ticker PBLA.
PBLA stock has fallen by −7.02% compared to the previous week, the month change is a −19.27% fall, over the last year Panbela Therapeutics, Inc. has showed a −40.73% decrease.
PBLA reached its all-time high on Feb 8, 2021 with the price of 211,411.2000 USD, and its all-time low was 0.2344 USD and was reached on May 1, 2025. View more price dynamics on PBLA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PBLA stock is 3.51% volatile and has beta coefficient of −0.91. Track Panbela Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Panbela Therapeutics, Inc. there?
Today Panbela Therapeutics, Inc. has the market capitalization of 1.15 M, it has decreased by −20.60% over the last week.
Yes, you can track Panbela Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Panbela Therapeutics, Inc. is going to release the next earnings report on May 26, 2025. Keep track of upcoming events with our Earnings Calendar.
PBLA net income for the last quarter is −7.17 M USD, while the quarter before that showed −7.14 M USD of net income which accounts for −0.46% change. Track more Panbela Therapeutics, Inc. financial stats to get the full picture.
No, PBLA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 24, 2025, the company has 8 employees. See our rating of the largest employees — is Panbela Therapeutics, Inc. on this list?
Like other stocks, PBLA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Panbela Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Panbela Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Panbela Therapeutics, Inc. stock shows the sell signal. See more of Panbela Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.